<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:cea91d24-2f27-4e54-b409-61f7d53cf6ee,g:6d57cee3-e605-4322-939b-44d12e050dd1,d:f010c4bb514347089e711ba63b7285f0--><html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2023" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>vrtx-20230517</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i9bce18c645e54a0b9332378d5921686a_D20230517-20230517" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmYwMTBjNGJiNTE0MzQ3MDg5ZTcxMWJhNjNiNzI4NWYwL3NlYzpmMDEwYzRiYjUxNDM0NzA4OWU3MTFiYTYzYjcyODVmMF8xMC9mcmFnOmJjNTkwMDkyOTAzNzRlYzc5YzIwODQ1YzM1YzljNDg1L3RhYmxlOjhkZDJjMDc3MGVjMTQ5OGZhNDNmOTg2ZTk4YWJmNDQwL3RhYmxlcmFuZ2U6OGRkMmMwNzcwZWMxNDk4ZmE0M2Y5ODZlOThhYmY0NDBfMi0xLTEtMS0xNzk3NTc_e598e66e-1d73-49d2-93a6-69586378f471">0000875320</ix:nonNumeric><ix:nonNumeric contextRef="i9bce18c645e54a0b9332378d5921686a_D20230517-20230517" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmYwMTBjNGJiNTE0MzQ3MDg5ZTcxMWJhNjNiNzI4NWYwL3NlYzpmMDEwYzRiYjUxNDM0NzA4OWU3MTFiYTYzYjcyODVmMF8xMC9mcmFnOmJjNTkwMDkyOTAzNzRlYzc5YzIwODQ1YzM1YzljNDg1L3RhYmxlOjhkZDJjMDc3MGVjMTQ5OGZhNDNmOTg2ZTk4YWJmNDQwL3RhYmxlcmFuZ2U6OGRkMmMwNzcwZWMxNDk4ZmE0M2Y5ODZlOThhYmY0NDBfMy0xLTEtMS0xNzk3NTc_ff180581-77f5-46e1-b770-7d2d40841ccc">VERTEX PHARMACEUTICALS INC / MA</ix:nonNumeric><ix:nonNumeric contextRef="i9bce18c645e54a0b9332378d5921686a_D20230517-20230517" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmYwMTBjNGJiNTE0MzQ3MDg5ZTcxMWJhNjNiNzI4NWYwL3NlYzpmMDEwYzRiYjUxNDM0NzA4OWU3MTFiYTYzYjcyODVmMF8xMC9mcmFnOmJjNTkwMDkyOTAzNzRlYzc5YzIwODQ1YzM1YzljNDg1L3RhYmxlOjhkZDJjMDc3MGVjMTQ5OGZhNDNmOTg2ZTk4YWJmNDQwL3RhYmxlcmFuZ2U6OGRkMmMwNzcwZWMxNDk4ZmE0M2Y5ODZlOThhYmY0NDBfNi0xLTEtMS0xNzk3NTc_6ec093b9-d365-4ca5-93ca-fd76bd9ac9ab">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="vrtx-20230517.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i9bce18c645e54a0b9332378d5921686a_D20230517-20230517"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875320</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-17</xbrli:startDate><xbrli:endDate>2023-05-17</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="if010c4bb514347089e711ba63b7285f0_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-bottom:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:232%">FORM <ix:nonNumeric contextRef="i9bce18c645e54a0b9332378d5921686a_D20230517-20230517" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmYwMTBjNGJiNTE0MzQ3MDg5ZTcxMWJhNjNiNzI4NWYwL3NlYzpmMDEwYzRiYjUxNDM0NzA4OWU3MTFiYTYzYjcyODVmMF8xL2ZyYWc6YTE3MDJjNjBlMTA5NDczMjk0OTM3MDlmNjczYzA2ZTAvdGV4dHJlZ2lvbjphMTcwMmM2MGUxMDk0NzMyOTQ5MzcwOWY2NzNjMDZlMF8xNjIw_50ee9b48-27a6-43d0-9216-0ade81c1859d">8-K</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported) <ix:nonNumeric contextRef="i9bce18c645e54a0b9332378d5921686a_D20230517-20230517" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmYwMTBjNGJiNTE0MzQ3MDg5ZTcxMWJhNjNiNzI4NWYwL3NlYzpmMDEwYzRiYjUxNDM0NzA4OWU3MTFiYTYzYjcyODVmMF8xL2ZyYWc6YTE3MDJjNjBlMTA5NDczMjk0OTM3MDlmNjczYzA2ZTAvdGV4dHJlZ2lvbjphMTcwMmM2MGUxMDk0NzMyOTQ5MzcwOWY2NzNjMDZlMF8yMjU_c029c31b-4087-44e2-a7c2-c9fdc5ad9d0b">May 17, 2023</ix:nonNumeric> </span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:144%">Vertex Pharmaceuticals Incorporated </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:144%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9bce18c645e54a0b9332378d5921686a_D20230517-20230517" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmYwMTBjNGJiNTE0MzQ3MDg5ZTcxMWJhNjNiNzI4NWYwL3NlYzpmMDEwYzRiYjUxNDM0NzA4OWU3MTFiYTYzYjcyODVmMF8xL2ZyYWc6YTE3MDJjNjBlMTA5NDczMjk0OTM3MDlmNjczYzA2ZTAvdGFibGU6ODRkZTU1ODM4MTU1NGIwOWJiZGExMTNkMDM3Y2NmODgvdGFibGVyYW5nZTo4NGRlNTU4MzgxNTU0YjA5YmJkYTExM2QwMzdjY2Y4OF8wLTAtMS0xLTE3OTc1Nw_933aa01f-5057-4c15-8542-5224dd319bbd">Massachusetts</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:144%"><ix:nonNumeric contextRef="i9bce18c645e54a0b9332378d5921686a_D20230517-20230517" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmYwMTBjNGJiNTE0MzQ3MDg5ZTcxMWJhNjNiNzI4NWYwL3NlYzpmMDEwYzRiYjUxNDM0NzA4OWU3MTFiYTYzYjcyODVmMF8xL2ZyYWc6YTE3MDJjNjBlMTA5NDczMjk0OTM3MDlmNjczYzA2ZTAvdGFibGU6ODRkZTU1ODM4MTU1NGIwOWJiZGExMTNkMDM3Y2NmODgvdGFibGVyYW5nZTo4NGRlNTU4MzgxNTU0YjA5YmJkYTExM2QwMzdjY2Y4OF8wLTEtMS0xLTE3OTc1Nw_1d6103d3-a290-4e70-99ba-f11589dd258d">000-19319</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9bce18c645e54a0b9332378d5921686a_D20230517-20230517" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmYwMTBjNGJiNTE0MzQ3MDg5ZTcxMWJhNjNiNzI4NWYwL3NlYzpmMDEwYzRiYjUxNDM0NzA4OWU3MTFiYTYzYjcyODVmMF8xL2ZyYWc6YTE3MDJjNjBlMTA5NDczMjk0OTM3MDlmNjczYzA2ZTAvdGFibGU6ODRkZTU1ODM4MTU1NGIwOWJiZGExMTNkMDM3Y2NmODgvdGFibGVyYW5nZTo4NGRlNTU4MzgxNTU0YjA5YmJkYTExM2QwMzdjY2Y4OF8wLTItMS0xLTE3OTc1Nw_4701cf7f-d613-41c7-99e5-ebf8face5f15">04-3039129</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(Commission File Number)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:144%"><ix:nonNumeric contextRef="i9bce18c645e54a0b9332378d5921686a_D20230517-20230517" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmYwMTBjNGJiNTE0MzQ3MDg5ZTcxMWJhNjNiNzI4NWYwL3NlYzpmMDEwYzRiYjUxNDM0NzA4OWU3MTFiYTYzYjcyODVmMF8xL2ZyYWc6YTE3MDJjNjBlMTA5NDczMjk0OTM3MDlmNjczYzA2ZTAvdGV4dHJlZ2lvbjphMTcwMmM2MGUxMDk0NzMyOTQ5MzcwOWY2NzNjMDZlMF8xNjIx_911da3b4-262f-4994-a21f-2b55cc936559">50 Northern Avenue</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:144%"><ix:nonNumeric contextRef="i9bce18c645e54a0b9332378d5921686a_D20230517-20230517" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmYwMTBjNGJiNTE0MzQ3MDg5ZTcxMWJhNjNiNzI4NWYwL3NlYzpmMDEwYzRiYjUxNDM0NzA4OWU3MTFiYTYzYjcyODVmMF8xL2ZyYWc6YTE3MDJjNjBlMTA5NDczMjk0OTM3MDlmNjczYzA2ZTAvdGV4dHJlZ2lvbjphMTcwMmM2MGUxMDk0NzMyOTQ5MzcwOWY2NzNjMDZlMF8xNjIy_595c0aeb-1b26-4694-83d4-b929bb5f7fe1">Boston</ix:nonNumeric>, <ix:nonNumeric contextRef="i9bce18c645e54a0b9332378d5921686a_D20230517-20230517" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmYwMTBjNGJiNTE0MzQ3MDg5ZTcxMWJhNjNiNzI4NWYwL3NlYzpmMDEwYzRiYjUxNDM0NzA4OWU3MTFiYTYzYjcyODVmMF8xL2ZyYWc6YTE3MDJjNjBlMTA5NDczMjk0OTM3MDlmNjczYzA2ZTAvdGV4dHJlZ2lvbjphMTcwMmM2MGUxMDk0NzMyOTQ5MzcwOWY2NzNjMDZlMF8xNjI3_e5908960-0388-4f73-98da-69d235baeaa9">Massachusetts</ix:nonNumeric>  <ix:nonNumeric contextRef="i9bce18c645e54a0b9332378d5921686a_D20230517-20230517" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmYwMTBjNGJiNTE0MzQ3MDg5ZTcxMWJhNjNiNzI4NWYwL3NlYzpmMDEwYzRiYjUxNDM0NzA4OWU3MTFiYTYzYjcyODVmMF8xL2ZyYWc6YTE3MDJjNjBlMTA5NDczMjk0OTM3MDlmNjczYzA2ZTAvdGV4dHJlZ2lvbjphMTcwMmM2MGUxMDk0NzMyOTQ5MzcwOWY2NzNjMDZlMF8xNjI4_9b154332-ffa3-4b06-82a4-aee3084ceb5e">02210</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:144%">(Address of principal executive offices) (Zip Code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:144%">(<ix:nonNumeric contextRef="i9bce18c645e54a0b9332378d5921686a_D20230517-20230517" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmYwMTBjNGJiNTE0MzQ3MDg5ZTcxMWJhNjNiNzI4NWYwL3NlYzpmMDEwYzRiYjUxNDM0NzA4OWU3MTFiYTYzYjcyODVmMF8xL2ZyYWc6YTE3MDJjNjBlMTA5NDczMjk0OTM3MDlmNjczYzA2ZTAvdGV4dHJlZ2lvbjphMTcwMmM2MGUxMDk0NzMyOTQ5MzcwOWY2NzNjMDZlMF8xNjIz_229280bf-d92b-44c5-8c0c-474fb2133808">617</ix:nonNumeric>) <ix:nonNumeric contextRef="i9bce18c645e54a0b9332378d5921686a_D20230517-20230517" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmYwMTBjNGJiNTE0MzQ3MDg5ZTcxMWJhNjNiNzI4NWYwL3NlYzpmMDEwYzRiYjUxNDM0NzA4OWU3MTFiYTYzYjcyODVmMF8xL2ZyYWc6YTE3MDJjNjBlMTA5NDczMjk0OTM3MDlmNjczYzA2ZTAvdGV4dHJlZ2lvbjphMTcwMmM2MGUxMDk0NzMyOTQ5MzcwOWY2NzNjMDZlMF8xNjI5_39012e7c-f13f-4075-9083-10f8e3cbafa7">341-6100</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">(Registrant's telephone number, including area code)</span></div><div style="padding-left:5.62pt;padding-right:5.62pt;text-align:center"><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span></div><div><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:174%"><ix:nonNumeric contextRef="i9bce18c645e54a0b9332378d5921686a_D20230517-20230517" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmYwMTBjNGJiNTE0MzQ3MDg5ZTcxMWJhNjNiNzI4NWYwL3NlYzpmMDEwYzRiYjUxNDM0NzA4OWU3MTFiYTYzYjcyODVmMF8xL2ZyYWc6YTE3MDJjNjBlMTA5NDczMjk0OTM3MDlmNjczYzA2ZTAvdGV4dHJlZ2lvbjphMTcwMmM2MGUxMDk0NzMyOTQ5MzcwOWY2NzNjMDZlMF8xNjMw_db80925c-7f85-41fb-96e6-5692757e62c9">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:174%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:174%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:174%"><ix:nonNumeric contextRef="i9bce18c645e54a0b9332378d5921686a_D20230517-20230517" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmYwMTBjNGJiNTE0MzQ3MDg5ZTcxMWJhNjNiNzI4NWYwL3NlYzpmMDEwYzRiYjUxNDM0NzA4OWU3MTFiYTYzYjcyODVmMF8xL2ZyYWc6YTE3MDJjNjBlMTA5NDczMjk0OTM3MDlmNjczYzA2ZTAvdGV4dHJlZ2lvbjphMTcwMmM2MGUxMDk0NzMyOTQ5MzcwOWY2NzNjMDZlMF8xNjI0_fab1779f-de6e-411d-866e-93d3cdb9eb93">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:174%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:174%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:174%"><ix:nonNumeric contextRef="i9bce18c645e54a0b9332378d5921686a_D20230517-20230517" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmYwMTBjNGJiNTE0MzQ3MDg5ZTcxMWJhNjNiNzI4NWYwL3NlYzpmMDEwYzRiYjUxNDM0NzA4OWU3MTFiYTYzYjcyODVmMF8xL2ZyYWc6YTE3MDJjNjBlMTA5NDczMjk0OTM3MDlmNjczYzA2ZTAvdGV4dHJlZ2lvbjphMTcwMmM2MGUxMDk0NzMyOTQ5MzcwOWY2NzNjMDZlMF8xNjE5_6fe27b2f-65da-4ffa-95a9-21a1035db3e6">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:174%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:174%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:174%"><ix:nonNumeric contextRef="i9bce18c645e54a0b9332378d5921686a_D20230517-20230517" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmYwMTBjNGJiNTE0MzQ3MDg5ZTcxMWJhNjNiNzI4NWYwL3NlYzpmMDEwYzRiYjUxNDM0NzA4OWU3MTFiYTYzYjcyODVmMF8xL2ZyYWc6YTE3MDJjNjBlMTA5NDczMjk0OTM3MDlmNjczYzA2ZTAvdGV4dHJlZ2lvbjphMTcwMmM2MGUxMDk0NzMyOTQ5MzcwOWY2NzNjMDZlMF8xNjI1_d736e611-0d67-4623-9f21-1c2205bde46c">&#9744;</ix:nonNumeric></span><span style="color:#231f20;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:174%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:174%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:35.942%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.615%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.237%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:58.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities registered pursuant to Section 12(b) of the Act:</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Title of each class</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trading Symbol</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9bce18c645e54a0b9332378d5921686a_D20230517-20230517" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmYwMTBjNGJiNTE0MzQ3MDg5ZTcxMWJhNjNiNzI4NWYwL3NlYzpmMDEwYzRiYjUxNDM0NzA4OWU3MTFiYTYzYjcyODVmMF8xL2ZyYWc6YTE3MDJjNjBlMTA5NDczMjk0OTM3MDlmNjczYzA2ZTAvdGFibGU6ZGU1YWJlNzNlNWVmNGE5MGI5Yzk1YzcyZTE5YjJmYTIvdGFibGVyYW5nZTpkZTVhYmU3M2U1ZWY0YTkwYjljOTVjNzJlMTliMmZhMl8yLTAtMS0xLTE3OTc1Nw_8f756315-ea74-40c9-9f1d-53df7253f5e9">Common Stock, $0.01 Par Value Per Share</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9bce18c645e54a0b9332378d5921686a_D20230517-20230517" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmYwMTBjNGJiNTE0MzQ3MDg5ZTcxMWJhNjNiNzI4NWYwL3NlYzpmMDEwYzRiYjUxNDM0NzA4OWU3MTFiYTYzYjcyODVmMF8xL2ZyYWc6YTE3MDJjNjBlMTA5NDczMjk0OTM3MDlmNjczYzA2ZTAvdGFibGU6ZGU1YWJlNzNlNWVmNGE5MGI5Yzk1YzcyZTE5YjJmYTIvdGFibGVyYW5nZTpkZTVhYmU3M2U1ZWY0YTkwYjljOTVjNzJlMTliMmZhMl8yLTItMS0xLTE3OTc1Nw_169946b2-8cac-4e91-8e4a-8b2dbc59329f">VRTX</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:11.25pt;padding-right:11.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9bce18c645e54a0b9332378d5921686a_D20230517-20230517" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmYwMTBjNGJiNTE0MzQ3MDg5ZTcxMWJhNjNiNzI4NWYwL3NlYzpmMDEwYzRiYjUxNDM0NzA4OWU3MTFiYTYzYjcyODVmMF8xL2ZyYWc6YTE3MDJjNjBlMTA5NDczMjk0OTM3MDlmNjczYzA2ZTAvdGFibGU6ZGU1YWJlNzNlNWVmNGE5MGI5Yzk1YzcyZTE5YjJmYTIvdGFibGVyYW5nZTpkZTVhYmU3M2U1ZWY0YTkwYjljOTVjNzJlMTliMmZhMl8yLTQtMS0xLTE3OTc1Nw_47684f12-a9fa-43f0-baa6-3ad9cc8352ac">The Nasdaq Global Select Market</ix:nonNumeric></span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div><span><br/></span></div><div><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i9bce18c645e54a0b9332378d5921686a_D20230517-20230517" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmYwMTBjNGJiNTE0MzQ3MDg5ZTcxMWJhNjNiNzI4NWYwL3NlYzpmMDEwYzRiYjUxNDM0NzA4OWU3MTFiYTYzYjcyODVmMF8xL2ZyYWc6YTE3MDJjNjBlMTA5NDczMjk0OTM3MDlmNjczYzA2ZTAvdGV4dHJlZ2lvbjphMTcwMmM2MGUxMDk0NzMyOTQ5MzcwOWY2NzNjMDZlMF8xNjI2_caea5c26-9476-401f-b0db-5738b3483291">&#9744;</ix:nonNumeric></span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="if010c4bb514347089e711ba63b7285f0_4"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:144%">Item 5.07&#160; Submission of Matters to a Vote of Security Holders</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:144%">The annual meeting of shareholders of Vertex Pharmaceuticals Incorporated (the "Company") was held on May&#160;17, 2023 (the "Annual Meeting"). Set forth below are the voting results for each of the proposals submitted to a vote of the Company's shareholders at the Annual Meeting:</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Proposal No. 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">: Based upon the following votes, the shareholders elected Sangeeta Bhatia, Lloyd Carney, Alan Garber, Terrence Kearney, Reshma Kewalramani, Jeffrey Leiden, Diana McKenzie, Bruce Sachs and Suketu Upadhyay to serve as members of the Company's Board of Directors until the annual meeting of shareholders to be held in 2024:</span></div><div style="margin-bottom:9pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"></td><td style="width:23.309%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.800%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Against</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Abstain</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Votes</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Sangeeta Bhatia</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,080,665</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,466,298</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,837</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,826,329</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Lloyd Carney</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,020,156</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,522,060</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,584</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,826,329</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Alan Garber</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,238,564</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,300,900</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,336</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,826,329</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Terrence Kearney</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212,386,123</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,155,694</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,983</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,826,329</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Reshma Kewalramani</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,944,919</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,605,123</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,758</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,826,329</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Jeffrey Leiden</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216,063,881</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,824,259</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">775,660</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,826,329</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Diana McKenzie</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,081,247</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,466,571</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,982</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,826,329</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Bruce Sachs</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203,818,027</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,714,176</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,597</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,826,329</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Suketu Upadhyay</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,991,778</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,551,263</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,759</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,826,329</span></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Proposal No. 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">: Based upon the following votes, the shareholders ratified the appointment of Ernst &amp; Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2023:</span></div><div style="margin-bottom:9pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"></td><td style="width:23.309%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.800%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Against</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Abstain</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Votes</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226,512,223</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,826,181</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,725</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Proposal No. 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">: Based upon the following votes, the shareholders approved, on an advisory basis, the 2022 compensation program for the Company's named executive officers:</span></div><div style="margin-bottom:9pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"></td><td style="width:23.309%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.800%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Against</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Abstain</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Votes</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,867,116</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,641,105</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,579</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,826,329</span></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Proposal No. 4:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Based upon the following votes, the shareholders recommended, on an advisory basis, to hold future advisory votes to approve executive compensation on an annual basis:</span></div><div style="margin-bottom:9pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.570%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1 Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2 Years</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3 Years</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Abstain</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Votes</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,845,689</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,872</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,607,838</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,401</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,826,329</span></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Based upon the results above, and consistent with the Board of Directors' recommendation, the Board has determined that future advisory votes on executive compensation will be submitted to shareholders on an annual basis until the next required vote on the frequency of such votes.</span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="if010c4bb514347089e711ba63b7285f0_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:144%">SIGNATURES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:144%">&#160; </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:144%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.888%"><tr><td style="width:1.0%"></td><td style="width:31.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:66.006%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">VERTEX PHARMACEUTICALS INCORPORATED</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:99pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(Registrant)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date:  May 18, 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">/s/ Jonathan Biller</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Jonathan Biller</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Executive Vice President, Chief Legal Officer</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
[{"type": "8-K", "sequence": "1", "filename": "vrtx-20230517.htm", "description": "8-K", "secsgml_size_bytes": 51197}]
{"company-data": {"conformed-name": "VERTEX PHARMACEUTICALS INC / MA", "cik": "0000875320", "assigned-sic": "2834", "irs-number": "043039129", "state-of-incorporation": "MA", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-19319", "film-number": "23933808"}, "business-address": {"street1": "50 NORTHERN AVENUE", "city": "BOSTON", "state": "MA", "zip": "02210", "phone": "6173416393"}, "mail-address": {"street1": "50 NORTHERN AVENUE", "city": "BOSTON", "state": "MA", "zip": "02210"}}
vrtx-20230517
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
May 17, 2023
Vertex Pharmaceuticals Incorporated
(Exact name of registrant as specified in its charter)
Massachusetts
000-19319
04-3039129
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
50 Northern Avenue
Boston
,
Massachusetts
02210
(Address of principal executive offices) (Zip Code)
(
617
)
341-6100
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
Common Stock, $0.01 Par Value Per Share
VRTX
The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07  Submission of Matters to a Vote of Security Holders
The annual meeting of shareholders of Vertex Pharmaceuticals Incorporated (the "Company") was held on May 17, 2023 (the "Annual Meeting"). Set forth below are the voting results for each of the proposals submitted to a vote of the Company's shareholders at the Annual Meeting:
Proposal No. 1
: Based upon the following votes, the shareholders elected Sangeeta Bhatia, Lloyd Carney, Alan Garber, Terrence Kearney, Reshma Kewalramani, Jeffrey Leiden, Diana McKenzie, Bruce Sachs and Suketu Upadhyay to serve as members of the Company's Board of Directors until the annual meeting of shareholders to be held in 2024:
For
Against
Abstain
Non-Votes
Sangeeta Bhatia
222,080,665
2,466,298
116,837
9,826,329
Lloyd Carney
209,020,156
15,522,060
121,584
9,826,329
Alan Garber
222,238,564
2,300,900
124,336
9,826,329
Terrence Kearney
212,386,123
12,155,694
121,983
9,826,329
Reshma Kewalramani
222,944,919
1,605,123
113,758
9,826,329
Jeffrey Leiden
216,063,881
7,824,259
775,660
9,826,329
Diana McKenzie
222,081,247
2,466,571
115,982
9,826,329
Bruce Sachs
203,818,027
20,714,176
131,597
9,826,329
Suketu Upadhyay
222,991,778
1,551,263
120,759
9,826,329
Proposal No. 2
: Based upon the following votes, the shareholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2023:
For
Against
Abstain
Non-Votes
226,512,223
7,826,181
151,725
0
Proposal No. 3
: Based upon the following votes, the shareholders approved, on an advisory basis, the 2022 compensation program for the Company's named executive officers:
For
Against
Abstain
Non-Votes
200,867,116
23,641,105
155,579
9,826,329
Proposal No. 4:
Based upon the following votes, the shareholders recommended, on an advisory basis, to hold future advisory votes to approve executive compensation on an annual basis:
1 Year
2 Years
3 Years
Abstain
Non-Votes
222,845,689
100,872
1,607,838
109,401
9,826,329
Based upon the results above, and consistent with the Board of Directors' recommendation, the Board has determined that future advisory votes on executive compensation will be submitted to shareholders on an annual basis until the next required vote on the frequency of such votes.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
VERTEX PHARMACEUTICALS INCORPORATED
(Registrant)
Date:  May 18, 2023
/s/ Jonathan Biller
Jonathan Biller
Executive Vice President, Chief Legal Officer